RxDoctor Payments Data

Steven Goldberg, MD

Interventional Cardiology · Great Falls, MTNPI 1548345374

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $102,900 of the $134,058 with a category attached, or 76.8%. Abbott accounts for 92.0% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2019 at $36,360 and has fallen 90.6% since, to $3,404 in 2025. Among interventional cardiology clinicians in MT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$134,058in general payments, 2019–2025

Across 242 payments — averaging $553.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$123K
  • Pfizer$7K
  • Medtronic$799
  • Heartflow, Inc.$504
  • Abiomed$331
  • Novartis$283
  • plus $2K from 19 others

What the payments were for

  • Consulting fees$102,90077%
  • Speaking & faculty fees$6,5505%
  • Travel & lodging$18,45414%
  • Food & beverage$6,1545%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$134,058 in reported general payments places this provider in the 95th percentile of 22 interventional cardiology providers in Montana.

See all interventional cardiology providers in Montana

Medicare billing

Part B allowed, 2024
$72,901
Medicare patients
977
Services billed
1,483

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis11$208,762
EliquisApixaban30$33,638
JardianceEmpagliflozin26$27,889
Praluent PenAlirocumab22$14,523
Metoprolol Succinate52$623
Losartan Potassium22$472
Atorvastatin Calcium32$444
Rosuvastatin Calcium23$378
Amlodipine Besylate28$370
Ezetimibe22$201
ClopidogrelClopidogrel Bisulfate17$180
Carvedilol14$106
Lisinopril11$15
Ramipril12$9

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$7,144$242,40141 claims
Boehringer IngelheimJardiance$56$27,88926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 22 interventional cardiology providers in Montana.

Other interventional cardiology in Great Falls

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →